L
Li Pang Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
High Impact
Researcher
faculty
22 h-index
84 pubs
2,534 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Li Pang's research focuses on investigating cardiotoxicity, particularly in the context of drug development and regulatory studies. Pang has explored the utility of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for assessing the cardiac safety of potential therapeutics, including oncology drugs like doxorubicin. This work involves developing and validating methods for using iPSC-CMs in nonclinical regulatory settings, considering factors such as serum effects and compound preparation that can influence delayed repolarization evaluations.
Further research by Pang extends to the development of novel drug delivery systems, such as cationic polymeric micellar structures designed for enhanced intramuscular transfection of mRNA-lipid nanoparticles. Additionally, Pang has investigated the impact of specific compounds on cellular functions, including the impairment of liver mitochondrial functions by pexidartinib in primary human hepatocytes. Other areas of study include the generation of reactive oxygen species using composite materials and the application of cardiac non-animal methods (NAMs) for toxicity screening and drug development.
Metrics
- h-index: 22
- Publications: 84
- Citations: 2,534
Selected Publications
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
New Alternative Methods in Drug Safety Assessment (2023)
-
Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment (2022)
-
Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs (2022)
Collaboration Network
Top Collaborators
Xi Yang
RTI International (US)
5 shared publications
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- New Alternative Methods in Drug Safety Assessment
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
William B. Mattes
Food and Drug Administration
3 shared publications
In database
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
Prathyusha Bagam
National Center for Toxicological Research
2 shared publications
In database
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
Qiang Shi
National Center for Toxicological Research
2 shared publications
In database
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- New Alternative Methods in Drug Safety Assessment
Lijun Ren
United States Food and Drug Administration
2 shared publications
In database
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
Katy S Papineau
National Center for Toxicological Research
2 shared publications
In database
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
Laura K. Schnackenberg
National Center for Toxicological Research
2 shared publications
In database
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
Wei Feng
United States Food and Drug Administration (US)
1 shared publication
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
Lisa Pence
United States Food and Drug Administration
1 shared publication
In database
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
Kellie A. Woodling
United States Food and Drug Administration
1 shared publication
In database
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
Richard D. Beger
National Center for Toxicological Research
1 shared publication
In database
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
Gonçalo Gamboa da Costa
United States Food and Drug Administration
1 shared publication
In database
- Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs
Alexandre J. S. Ribeiro
Center for Drug Evaluation and Research (US)
1 shared publication
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
David G. Strauss
United States Food and Drug Administration (US)
1 shared publication
- Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment
Minjun Chen
National Center for Toxicological Research
1 shared publication
In database
- New Alternative Methods in Drug Safety Assessment
Similar Researchers
Based on overlapping research topics
J.C. Hsu
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
Mitochondrial Function and Pathology
Alicja Urbaniak
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Nanoparticles: synthesis and applications
Drug Delivery Systems
Alexei G. Basnakian
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Mitochondrial Function and Pathology
Nanoparticles: synthesis and applications
Gretchen Holtgrefe
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Nanoparticles: synthesis and applications
Cancer Treatment and Pharmacology
Mehta Jl
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
Mitochondrial Function and Pathology
Ashim K. Bagchi
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cardiovascular Function and Risk Factors
Mitochondrial Function and Pathology